{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:56:07Z","timestamp":1781632567757,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The increasing availability of biosimilars has raised important questions regarding their interchangeability with originator biologics in the treatment of immune-mediated rheumatic diseases. Addressing this issue is critical to ensuring patient safety, therapeutic efficacy, and informed clinical decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To present a position statement from the Biotechnology Committee of the Brazilian Society of Rheumatology on the interchangeability between originator and biosimilar biologic drugs in rheumatologic care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A task force of 22 rheumatologists with expertise in immunobiological therapies followed a structured three-phase consensus process: (1) development of five key questions on biosimilar interchangeability; (2) comprehensive literature review using MEDLINE, EMBASE, and LILACS databases; and (3) final review and endorsement by relevant BSR committees. Expert opinion was used when evidence was limited or inconclusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The position statement comprises five consensus-based recommendations, all unanimously supported by the task force, and supported by current scientific evidence and clinical experience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The Biotechnology Committee of the Brazilian Society of Rheumatology endorses the safe and effective interchangeability of originator and biosimilar biologics when guided by principles that ensure patient safety, therapeutic continuity, and healthcare system sustainability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42358-026-00523-5","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T07:47:48Z","timestamp":1769759268000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Position statement of the Biotechnology Committee of the Brazilian Society of Rheumatology on the interchangeability of originator and biosimilar biologics in immune-mediated rheumatic diseases"],"prefix":"10.1186","volume":"66","author":[{"given":"Paulo Chicarone","family":"Pereira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel Alexandre","family":"Yazbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela Bicalho Viana","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana Miranda","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Lu\u00edz","family":"Boechat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio Cesar Bertacini","family":"de Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Machado","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hellen Mary da Silveira de","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda de Miranda","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Airton Castro","family":"da Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana Pompeo","family":"de Pina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Gon\u00e7alves Schahin","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Diniz Lopes","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina Rossi","family":"Bonfiglioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cristina de Medeiros","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Eduardo","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licia Maria Henrique","family":"da Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Antonio Ara\u00fajo","family":"da Rocha-Loures","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivanio Alves","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Goldenstein","family":"Schainberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Ibrahim","family":"Uehbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2346-388X","authenticated-orcid":false,"given":"Valderilio Feij\u00f3","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"523_CR1","unstructured":"US, Food, and Drug Administration (FDA). Development of therapeutic protein biosimilars: comparative analytical assessment other quality-related considerations. Guidance for Industry. 2023. Available from: https:\/\/www.fda.gov\/media\/159261\/download."},{"issue":"4","key":"523_CR2","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cpt.1836","volume":"108","author":"L - Barbier","year":"2020","unstructured":"Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020;108(4):734\u201355. https:\/\/doi.org\/10.1002\/cpt.1836.","journal-title":"Clin Pharmacol Ther"},{"key":"523_CR3","unstructured":"European Medicines Agency (EMA). Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. April 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf."},{"key":"523_CR4","unstructured":"US. Food and Drug Administration (FDA). Biosimilar product regulatory review and approval. Available from: https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information."},{"key":"523_CR5","unstructured":"European Medicines Agency (EMA). What is a biosimilar? Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/biosimilar-medicines-overview."},{"key":"523_CR6","unstructured":"World Health Organization (WHO). Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. Available from: https:\/\/www.who.int\/publications\/m\/item\/WHO-BS-09.2159."},{"key":"523_CR7","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA). Nota T\u00e9cnica n\u00ba 61\/2022\/SEI\/GPBIO\/GGBIO\/DIRE2\/ANVISA. Available from: https:\/\/www.gov.br\/anvisa\/pt-br\/setorregulado\/regularizacao\/medicamentos\/produtos-biologicos\/documentos-orientativos-e-guias\/nt-61_2022_gpbio_biossimilares.pdf."},{"key":"523_CR8","unstructured":"European Medicines Agency (EMA). Biosimilars in the EU \u2013 Information Guide for Healthcare Professionals. 2017."},{"key":"523_CR9","unstructured":"US. Food and Drug Administration (FDA). Considerations in demonstrating interchangeability with a reference product. 2019."},{"issue":"5","key":"523_CR10","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s10067-019-04496-3","volume":"38","author":"SC - Kowalski","year":"2019","unstructured":"Kowalski SC, Benavides JA, Roa PAB, Galarza-Maldonado C, Caballero-Uribe CV, Soriano ER, et al. PANLAR consensus statement on biosimilars. Clin Rheumatol. 2019;38(5):1485\u201396.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"523_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s43441-024-00716-4","volume":"59","author":"KA - Alnaqbi","year":"2025","unstructured":"Alnaqbi KA, Al-Jedai A, Farghaly M, Omair MA, Hamad A, Abutiban FMA, et al. Expert consensus recommendations on a biosimilars value framework for the Gulf Cooperation Council countries. Ther Innov Regul Sci. 2025;59(1):153\u201363.","journal-title":"Ther Innov Regul Sci"},{"issue":"5","key":"523_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40259-022-00546-6","volume":"36","author":"HP - Cohen","year":"2022","unstructured":"Cohen HP, Hachaichi S, Bodenmueller W, Kvien TK, Danese S, Blauvelt A. Switching from one biosimilar to another biosimilar of the same reference biologic: A systematic review of studies. BioDrugs. 2022;36(5):625\u201337. https:\/\/doi.org\/10.1007\/s40259-022-00546-6.","journal-title":"BioDrugs"},{"issue":"2","key":"523_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2017-211937","volume":"77","author":"J - Kay","year":"2018","unstructured":"Kay J, Schoels MM, D\u00f6rner T, Emery P, Kvien TK, Smolen JS, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77(2):165\u201374.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"523_CR14","doi-asserted-by":"publisher","first-page":"e0292231","DOI":"10.1371\/journal.pone.0292231","volume":"18","author":"TM -Herndon","year":"2023","unstructured":"Herndon TM, Ausin C, Brahme NN, Schrieber SJ, Luo M, Andrada FC, et al. Safety outcomes when switching between biosimilars and reference biologics: A systematic review and meta-analysis. PLoS ONE. 2023;18(10):e0292231. https:\/\/doi.org\/10.1371\/journal.pone.0292231. PMID: 37788264; PMCID: PMC10547155.","journal-title":"PLoS ONE"},{"key":"523_CR15","unstructured":"American College of Rheumatology. ACR Position Statement: Biosimilars. 2024. Available from: https:\/\/rheumatology.org\/Portals\/0\/Files\/Biosimilars-Position-Statement.pdf"},{"key":"523_CR16","unstructured":"American College of Rheumatology. RE: considerations in demonstrating interchangeability with a reference product: update. Deborah Dyett Desir, MD. President, American College of Rheumatology., 2024. Available from: https:\/\/assets.contentstack.io\/v3\/assets\/bltee37abb6b278ab2c\/blt1beaaa3f4e28ff65\/advocacy-letter-fda-interchangeability-guidance-comments.pdf"},{"issue":"10086","key":"523_CR17","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK - J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen KK, Olsen IC, Goll GL, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Switching from originator Infliximab to biosimilar CT-P13 compared with maintained treatment with originator Infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304\u201316. https:\/\/doi.org\/10.1016\/S0140-67361730068-5.","journal-title":"Lancet"},{"issue":"2","key":"523_CR18","first-page":"80","volume":"16","author":"V - Azevedo","year":"2024","unstructured":"Azevedo V, Rezende M, Brovini RR, Odebrecht PC, Moreira BE, Guadagnim TH. Custo-minimiza\u00e7\u00e3o e gerenciamento de Trocas entre produtos de refer\u00eancia e Seus biossimilares no sistema privado de sa\u00fade no brasil: o Caso Da unimed Maring\u00e1. JBES - J Bras Econ Sa\u00fade. 2024;16(2):80\u20136.","journal-title":"JBES - J Bras Econ Sa\u00fade"},{"key":"523_CR19","doi-asserted-by":"publisher","first-page":"100783","DOI":"10.37349\/emd.2025.100783","volume":"3","author":"FA - Reyes Neira","year":"2025","unstructured":"Reyes Neira FA, Bayeh B, Bonfiglioli KR, Aikawa NE, Assad APL, Miossi R, et al. Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with axial spondyloarthritis: a 12-month observational study. Explor Musculoskelet Dis. 2025;3:100783. https:\/\/doi.org\/10.37349\/emd.2025.100783.","journal-title":"Explor Musculoskelet Dis"},{"issue":"11","key":"523_CR20","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1007\/s12325-020-01433-2","volume":"37","author":"G - Casta\u00f1eda-Hern\u00e1ndez","year":"2020","unstructured":"- Casta\u00f1eda-Hern\u00e1ndez G, Faccin F, Heaney J, et al. The challenges of switching therapies in an evolving multiple biosimilars landscape: a narrative review of current evidence. Adv Ther. 2020;37(11):4491\u2013518. https:\/\/doi.org\/10.1007\/s12325-020-01433-2.","journal-title":"Adv Ther"},{"issue":"7","key":"523_CR21","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.3390\/jpm12071174","volume":"12","author":"M - Benucci","year":"2022","unstructured":"- Benucci M, Damiani A, Russo E, Li Gobbi F, Grossi V, Amedei A, et al. Predicting loss of efficacy after non-medical switching: correlation between Circulating TNF-\u03b1 levels and SB4 in etanercept to SB4 switchers and na\u00efve patients with rheumatic disease. J Pers Med. 2022;12(7):1174. https:\/\/doi.org\/10.3390\/jpm12071174.","journal-title":"J Pers Med"},{"key":"523_CR22","doi-asserted-by":"publisher","unstructured":"Feagan BG, Marabani M, Wu JJ, Faccin F, Spronk C, Casta\u00f1eda-Hern\u00e1ndez G. The challenges of switching therapies in an evolving multiple biosimilars landscape: a narrative review of current evidence. Adv Ther. 2020;37(11):4491\u20134518. https:\/\/doi.org\/10.1007\/s12325-020-01443-3. PMID: 32909159.","DOI":"10.1007\/s12325-020-01443-3"},{"key":"523_CR23","doi-asserted-by":"publisher","unstructured":"Kurki P, Barry S, Bourges I, Tsantili P, Xerri L, Wolff-Holz E, Weise M. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021;81(15):1881\u20131896. https:\/\/doi.org\/10.1007\/s40265-021-01601-2. PMID: 34347270.","DOI":"10.1007\/s40265-021-01601-2"},{"key":"523_CR24","doi-asserted-by":"publisher","first-page":"917814","DOI":"10.3389\/fphar.2022.917814","volume":"13","author":"E - Allocati","year":"2022","unstructured":"Allocati E, Godman B, Gobbi M, Garattini S, Banzi R. Switching among biosimilars: A review of clinical evidence. Front Pharmacol. 2022;13:917814. https:\/\/doi.org\/10.3389\/fphar.2022.917814.","journal-title":"Front Pharmacol"},{"key":"523_CR25","doi-asserted-by":"publisher","first-page":"175628482413018","DOI":"10.1177\/17562848241301887","volume":"17","author":"S - Fischer","year":"2024","unstructured":"Fischer S, Donhauser M, Cohnen S, Fietkau K, Vetter M, Gr\u00fcbel-Liehr M, et al. Reverse switching from the biosimilar SB2 to the originator Infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study. Th Adv Gastroenterol. 2024;17:17562848241301887. https:\/\/doi.org\/10.1177\/17562848241301887. PMID: 39619829; PMCID: PMC11608450.","journal-title":"Th Adv Gastroenterol"},{"issue":"6","key":"523_CR26","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1001\/jamainternmed.2020.0338","volume":"180","author":"TB - Jensen","year":"2020","unstructured":"Jensen TB, Kim SC, Jimenez Solem E, Bartels D, Christensen HR, Andersen JT. Shift from adalimumab originator to biosimilars in Denmark. JAMA Intern Med. 2020;180(6):902\u20133. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0338. PMID: 32227137; PMCID: PMC7105946.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"523_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40744-017-0085-z","volume":"4","author":"MF - Rezk","year":"2017","unstructured":"Rezk MF, Pieper B. Treatment outcomes with biosimilars: be aware of the Nocebo effect. Rheumatol Ther. 2017;4(2):209\u201318. https:\/\/doi.org\/10.1007\/s40744-017-0085-z.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"523_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1080\/14397595.2019.1609936","volume":"30","author":"SY - Kawashiri","year":"2020","unstructured":"Kawashiri SY, Gotoh L, Furukawa H, et al. Switching from originator Infliximab to biosimilar Infliximab in Japanese patients with rheumatoid arthritis achieving clinical remission. Mod Rheumatol. 2020;30(1):60\u20136. https:\/\/doi.org\/10.1080\/14397595.2019.1609936.","journal-title":"Mod Rheumatol"},{"issue":"5","key":"523_CR29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40265-022-01691-7","volume":"82","author":"HP - Cohen","year":"2022","unstructured":"Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G. Switching among biosimilars: A review of clinical evidence. Drugs. 2022;82(5):523\u201337. https:\/\/doi.org\/10.1007\/s40265-022-01691-7.","journal-title":"Drugs"},{"issue":"5","key":"523_CR30","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-019-01088-0","volume":"79","author":"J - Kowalski","year":"2019","unstructured":"Kowalski J, Gandhi K, Jin Y, Skup M, Heidbuchel H, Weinblatt ME. Switching between reference biologics and biosimilars for the treatment of immune-mediated inflammatory diseases: considerations for policy makers. Drugs. 2019;79(5):463\u201378. https:\/\/doi.org\/10.1007\/s40265-019-01088-0.","journal-title":"Drugs"},{"issue":"1","key":"523_CR31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s40259-021-00508-4","volume":"36","author":"HP - Cohen","year":"2022","unstructured":"Cohen HP, McCabe D, McKinnon RA, et al. Expert consensus recommendations on a biosimilars value framework. BioDrugs. 2022;36(1):27\u201338.","journal-title":"BioDrugs"},{"issue":"1","key":"523_CR32","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5639\/gabij.2023.1201.004","volume":"12","author":"JB - Herndon","year":"2023","unstructured":"Herndon JB, Xie F, Curtis JR. Misinformation about interchangeable biosimilars undermines US health policy, physician confidence, and patient access. GaBI J. 2023;12(1):12\u20136.","journal-title":"GaBI J"},{"key":"523_CR33","unstructured":"European Medicines Agency (EMA). Questions and answers on biosimilar medicines (similar biological medicinal products). 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/questions-answers-biosimilar-medicines-similar-biological-medicinal-products_en.pdf"},{"issue":"6","key":"523_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/ejhpharm-2022-003571","volume":"29","author":"S - Kohl","year":"2022","unstructured":"Kohl S. EMA\/HMA joint statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. Eur J Hosp Pharm. 2022;29(6):363.","journal-title":"Eur J Hosp Pharm"},{"issue":"1","key":"523_CR35","doi-asserted-by":"publisher","first-page":"e001692","DOI":"10.1136\/rmdopen-2021-001692","volume":"7","author":"B - Glintborg","year":"2021","unstructured":"Glintborg B, Lindstr\u00f6m U, Aaltonen K, et al. Second biosimilar wave: Follow-up of 2876 patients after switch from originator to biosimilar adalimumab in clinical practice. Results from the nordic NOR-CARE study. RMD Open. 2021;7(1):e001692. https:\/\/doi.org\/10.1136\/rmdopen-2021-001692.","journal-title":"RMD Open"},{"key":"523_CR36","volume-title":"Auditoria Em medicamentos de Alto custo: Boas pr\u00e1ticas Na gest\u00e3o cl\u00ednica e administrativa de terapias imunobiol\u00f3gicas. 2\u00aa ed","author":"VF - Azevedo","year":"2024","unstructured":"Azevedo VF. Auditoria Em medicamentos de Alto custo: Boas pr\u00e1ticas Na gest\u00e3o cl\u00ednica e administrativa de terapias imunobiol\u00f3gicas. 2\u00aa ed. Fortaleza: Gr\u00e1fica LCR; 2024."},{"key":"523_CR37","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA). Resolu\u00e7\u00e3o da Diretoria Colegiada \u2013 RDC n\u00ba 875, de 20 de mar\u00e7o de 2024. Disp\u00f5e sobre as diretrizes para o registro de medicamentos biossimilares. Di\u00e1rio Oficial da Uni\u00e3o. 21. mar 2024; Se\u00e7\u00e3o 1:122."},{"key":"523_CR38","doi-asserted-by":"publisher","first-page":"SP545","DOI":"10.37765\/ajmc.2023.89419","volume":"29","author":"S - Humphreys","year":"2023","unstructured":"Humphreys S. Understanding interchangeable biosimilars at the federal and state levels. Am J Manag Care. 2023;29:SP545\u20138. https:\/\/doi.org\/10.37765\/ajmc.2023.89419. 7 Spec No.).","journal-title":"Am J Manag Care"},{"key":"523_CR39","unstructured":"US. Food and Drug Administration. 9 things to know about biosimilars and interchangeable biosimilars. 2024. Available from: https:\/\/www.fda.gov\/drugs\/things-know-about\/9-things-know-about-biosimilars-and-interchangeable-biosimilars"},{"key":"523_CR40","unstructured":"Golec J, McKnight M, Mulcahy A, Skiermont K, Colbert J. Advocacy letter to the FDA on interchangeability guidance for biosimilars. Alliance for Safe Biologic Medicines (ASBM); 2024. Available from: https:\/\/www.regulations.gov\/comment\/FDA-2020-D-0530-0056."},{"key":"523_CR41","unstructured":"American College of Rheumatology. ACR Position Statement: Biosimilars. Atlanta, GA: ACR. 2024. Available from: https:\/\/rheumatology.org\/patients\/biosimilars"},{"issue":"6","key":"523_CR42","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1007\/s12325-023-02415-1","volume":"40","author":"TM - Herndon","year":"2023","unstructured":"Herndon TM, Johnson JK, Leung J, Anderson S, Hennessy S. Considerations for biosimilar adoption and interchangeability: A U.S. FDA perspective. Adv Ther. 2023;40(6):2471\u201388. https:\/\/doi.org\/10.1007\/s12325-023-02415-1.","journal-title":"Adv Ther"},{"issue":"7","key":"523_CR43","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s12325-019-00981-5","volume":"36","author":"SC - Kowalski","year":"2019","unstructured":"Kowalski SC, McCormick N, DeGuire P, Levy AR. Knowledge, attitudes, and perceptions of biosimilars among specialty physicians. Adv Ther. 2019;36(7):1833\u201345. https:\/\/doi.org\/10.1007\/s12325-019-00981-5.","journal-title":"Adv Ther"},{"key":"523_CR44","doi-asserted-by":"publisher","first-page":"175628482412475","DOI":"10.1177\/17562848241247532","volume":"17","author":"S - Fischer","year":"2024","unstructured":"Fischer S, Heymann F, Harris S, Thomsen SB, Steenholdt C. Reverse switching from the biosimilar SB2 to the originator Infliximab in previously switched patients with inflammatory bowel diseases. Ther Adv Gastroenterol. 2024;17:17562848241247532. https:\/\/doi.org\/10.1177\/17562848241247532.","journal-title":"Ther Adv Gastroenterol"},{"key":"523_CR45","unstructured":"2\u00ba. Workshop on Biologicals and Biosimilars \u2013 ANVISA \u2013 Dez\/2023 \u2013 https:\/\/m.youtube.com\/watch?v=Zja42cV2XnA. https:\/\/gabionline.net\/biosimilars\/general\/brazil-advances-in-follow-on-biologicals-biosimilars-approvals-trailing-europe."},{"key":"523_CR46","doi-asserted-by":"publisher","unstructured":"Rathore AS, Stevenson JG, Chhabra H, Maharana C. The global landscape on interchangeability of biosimilars. Expert Opin Biol Ther. 2022;22(2):133\u2013148. https:\/\/doi.org\/10.1080\/14712598.2021.1889511 Epub 2021 May 6. PMID: 33567923.","DOI":"10.1080\/14712598.2021.1889511"},{"issue":"16","key":"523_CR47","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s40265-021-01610-1","volume":"81","author":"E - Mysler","year":"2021","unstructured":"Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, Mueller M, Peyrin-Biroulet L. Biosimilar-to-Biosimilar switching: what is the rationale and current. Experience? Drugs. 2021;81(16):1859\u201379.","journal-title":"Experience? Drugs"},{"issue":"2","key":"523_CR48","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ueg2.12357","volume":"11","author":"B - Gros","year":"2023","unstructured":"Gros B, Plevris N, Constantine-Cooke N, Lyons M, O\u2019Hare C, Noble C, Arnott ID, Jones GR, Lees CW, Derikx LAAP. Multiple Infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort. United Eur Gastroenterol J. 2023;11(2):179\u201388. Epub 2023 Feb 17. PMID: 36802176; PMCID: PMC10039791.","journal-title":"United Eur Gastroenterol J"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-026-00523-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-026-00523-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-026-00523-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:23:08Z","timestamp":1781630588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s42358-026-00523-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["523"],"URL":"https:\/\/doi.org\/10.1186\/s42358-026-00523-5","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"6 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Alexandre Ibrahim Uehbe declares have received consulting and speaker fees from Abbvie, Janssen, Novartis, Fresenius Kabi, Argentina, Theramex.Amanda de Miranda Marques declares to be part of the Section Medical affairs of Bio-Manguinhos\/FiocruzAntonio Luiz Boechcar declares have received Consulting fees of Abbvie, Pfizer and Janssen. Fabiana Miranda Moura declares to be a speaker and have received consulting fees from GSK, Janssen, Celltrion and LillFrancisco Airton Castro de Rocha declares have received consulting fees from Abbvie, Abbott, Ach\u00e9, Adium, Celltrion, Janssen, Lilly, Janssen, Viatris and Zambom. Helen Mary da Silveira de Carvalho declares have received Consulting fees from Abbvie, Amgen, Fresenius Kabi, Janssen, Libbs, Lilly, Novartis, Pfizer, Sandoz, UCBJulio Cesar Bertacini de Moraes declares partipations in congress and courses sponsored by Lilly and Fresenius Kabi.Licia Maria Henrique da Motta declares have received personal or institutional support from Abbvie, Janssen, Pfizer, Lilly. She also has delivered speeches at events related to this work and sponsored by Abbvie, Janssen, Pfizer, Lilly, Organon, Boehringer-Ingelheim, Celltrion, UCB. Michel Alexandre Yazbek declares have received consulting and speaker fees from Abbvie, Novartis, Lilly, Janssen, UCB, Organon, Fresenius Kabi and Sandoz. Rafaela Bicalho declares have received consulting fees from janssen, Celltrion, Lilly and UCBRicardo Machado Xavier declares to be a speaker of Abbvie, UCB, GSK, Sandoz and NovartisValder\u00edlio Feij\u00f3 Azevedo declares have received consulting fees and research grants from Abbvie, Abbott, Janssen, Celltrion, Organon, Takeda, Sandoz, Amgen, GSK, AstraZeneca, Fresenius Kabi and Boehringer-IngelheimThe other authors declares no conflicts of interest to be part of this statement.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}